Zymeworks Inc.

NasdaqGS:ZYME Voorraadrapport

Marktkapitalisatie: US$914.7m

Zymeworks Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Zymeworks has been growing earnings at an average annual rate of 21.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 37.8% per year.

Belangrijke informatie

21.8%

Groei van de winst

28.8%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei37.8%
Rendement op eigen vermogen-31.0%
Nettomarge-182.8%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 03
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Nov 01
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Aug 07
Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Jul 26
Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Zymeworks: A Somewhat Complicated Story

Jul 09

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Jun 12
Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

May 03
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Apr 18

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Mar 05

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Feb 06

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

Zymeworks: A Roller Coaster Year

Jul 26

Zymeworks And The Blue Falcon Elucidation

May 17

Opbrengsten en kosten

Hoe Zymeworks geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:ZYME Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 2462-114600
30 Jun 2463-113630
31 Mar 2450-126690
31 Dec 2376-119700
30 Sep 23462205870
30 Jun 23448186860
31 Mar 23446173800
31 Dec 22412124750
30 Sep 2230-224490
30 Jun 2232-237490
31 Mar 2228-240530
31 Dec 2127-212420
30 Sep 2122-211500
30 Jun 2121-223560
31 Mar 2131-194490
31 Dec 2039-181550
30 Sep 2025-215720
30 Jun 2030-173630
31 Mar 2026-163620
31 Dec 1930-145630
30 Sep 1957-64400
30 Jun 1951-52360
31 Mar 1965-29310
31 Dec 1853-37300
30 Sep 1874-13280
30 Jun 1872-11260
31 Mar 1852-16190
31 Dec 1752-11180
30 Sep 174-55190
30 Jun 176-51160
31 Mar 1711-47170
31 Dec 1611-34130
30 Sep 1610-3090
31 Dec 1510-1950
31 Dec 142-1340

Kwaliteitswinsten: ZYME is currently unprofitable.

Groeiende winstmarge: ZYME is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: ZYME is unprofitable, but has reduced losses over the past 5 years at a rate of 21.8% per year.

Versnelling van de groei: Unable to compare ZYME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: ZYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: ZYME has a negative Return on Equity (-30.97%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden